首页> 外文期刊>Italian journal of pediatrics >Long-term outcome of a patient with Transcobalamin deficiency caused by the homozygous c.1115_1116delCA mutation in TCN2 gene: a case report
【24h】

Long-term outcome of a patient with Transcobalamin deficiency caused by the homozygous c.1115_1116delCA mutation in TCN2 gene: a case report

机译:TCN2基因纯合C.1115_1116delca突变引起的患者的长期结果是TCN2基因的突变:案例报告

获取原文
           

摘要

Transcobalamin deficiency is a rare autosomal recessive inborn error of cobalamin transport (prevalence: ?1/1000000) which clinically manifests in early infancy. We describe the case of a 31?years old woman who at the age of 30?days presented with the classical clinical and laboratory signs of an inborn error of vitamin B12 metabolism. Family history revealed a sister who died at the age of 3?months with a similar clinical syndrome and with pancytopenia. She was started on empirical intramuscular (IM) cobalamin supplements (injections of hydroxocobalamin 1?mg/day for 1?week and then 1?mg twice a week) and several transfusions of washed and concentrated red blood cells. With these treatments a clear improvement in symptoms was observed, with the disappearance of vomiting, diarrhea and normalization of the full blood count. At 8?years of age injections were stopped for about two and a half months causing the appearance of pancytopenia. IM hydroxocobalamin was then restarted sine die. The definitive diagnosis could only be established at 29?years of age when a genetic evaluation revealed the homozygous c.1115_1116delCA mutation of TCN2 gene (p.Q373GfsX38). Currently she is healthy and she is taking 1?mg of IM hydroxocobalamin once a week. Our case report highlights that early detection of TC deficiency and early initiation of aggressive IM treatment is likely associated with disease control and an overall favorable outcome.
机译:转基霉素缺乏是一种稀有的胃巴胺转运的纯血栓溶膜隐性天生误差(患病率:& 1/1000000),其在早期婴儿期临床表现出来。我们描述了31岁的案例,年龄在30岁时的历史,并介绍了维生素B12代谢的典型临床和实验室迹象。家庭历史揭示了一个在3岁时死亡的妹妹,患有类似的临床综合征和韧皮病症。她开始在经验肌肉内(IM)钴胺蛋白补充剂(注射羟波钴胺1?Mg /天1?周,然后每周两次,然后是1?Mg),并对洗涤和浓缩的红细胞进行几种输血。通过这些治疗,观察到症状的显性改善,随着呕吐,腹泻和全血计的标准化而消失。在8年内注射率为大约两年半的注射,导致韧皮病的出现。然后重新启动羟化钴胺素正弦模具。当遗传评估揭示TCN2基因的纯合C.1115_1116delca突变时,最终诊断只能在29岁时建立(P.Q373GFSX38)。目前她每周服用一次1?Mg IM羟桶酰胺。我们的案例报告突出显示,早期检测TC缺乏和早期开始的侵略性IM治疗可能与疾病控制和整体有利结果有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号